AIR-DOCTOR
31.5.2022 12:02:03 CEST | Business Wire | Press release
Medical care and travel startup Air Doctor has secured $20M in funding for scaling the company globally. This second round of investment capitalizes on the worldwide influx in travelers after the Covid-19 pandemic and will enable the company to enter its next phase of growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220531005013/en/
Air Doctor, raised $20 million, led by Lightspeed Venture Partners. Joining this round are Vintage Investment Partners and Munich Re Ventures, alongside The Phoenix , one of Israel's leading insurance providers, as well as Kamet Ventures , which led the company’s previous round.
Founded by Jenny Cohen Derfler, Efrat Sagi Ofir, Yam Derfler and Yegor Kurbachev, Air Doctor has previously raised $10.9 million since its launch in 2018. The startup currently employs over 60 people based in Israel and Europe.
The Air Doctor platform connects travelers who fall ill abroad with local private doctors through an easy-to-use mobile and web app. Air Doctor’s outpatient medical network covers 74 countries and includes over 20,000 medical professionals who provide either in-person or telemedicine consultations. Following the Covid-19 pandemic, medical assistance while traveling has become a major concern for travelers and insurers alike. Air Doctor’s platform provides the assurance travelers need to enjoy their trip.
In addition to bringing on board more developers to work on product customization, Air Doctor will use the new investment to hire new employees and open additional offices internationally. The company also has plans to expand the product and marketing teams, and the vetted medical professional network, particularly in the US and Europe.
In 2020, the COVID-19 outbreak brought the world to a standstill, with unprecedented and unanticipated consequences affecting people's lives and global economies. The travel and tourism sector experienced a severe economic slowdown as a result of stringent quarantine regulations and travel restrictions.
“As the world emerges from COVID-19, people have resumed travel, with a greater demand for suitable travel insurance and digital solutions. The pandemic has forced the industry to reassess local medical treatment available for travelers. Today, travelers testing positive for the Coronavirus will be able to seek medical care in the local communities they are in rather than in hospitals.” said Jenny Cohen Derfler, CEO and Founder of Air Doctor. “Air Doctor has become one of the fastest-growing startups, with tens of thousands registered users and many more accessing the network worldwide. Today the company offers a unique and distinctive digital product with almost no competition worldwide.” Said CEO Cohen Derfler
According to the World Economic Forum’s recent survey , the travel industry is expected to fully recover by 2024. Additionally, many countries may mandate travel insurance coverage. These two factors will create a dramatic surge in the need for better travel insurance. Furthermore, insurers facing travelers’ demands are seeking to expand their offer of digital, physical and online healthcare coverage to provide an improved customer experience and reduce claim costs.
“Building our partner and investor network will be an ongoing endeavor, as well as boosting our R&D capabilities and end-user activation. We’re also on the lookout to find new team members who are keen to join an exciting startup that is expanding globally,” said Efrat Sagi-Ofir, Co-Founder and Chief Revenue Officer of Air Doctor.
“Air Doctor addresses a major pain point for the health and travel insurance industry, and Lightspeed is excited to lead the company’s new $20 million funding round. Air Doctor continues to prove itself as an innovator in travel health by digitizing a significant aspect of the travel experience,” said Yoni Cheifetz, Partner at Lightspeed. “
About Air Doctor
Launched in Israel in 2018, Air Doctor is a startup that connects travelers seeking medical attention with local doctors whilst abroad through their intuitive mobile and desktop app. With a global network of over 20,000 medical professionals across 2,000 cities in 74 countries, Air Doctor provides travelers with peace of mind and aims to make healthcare accessible to everyone, everywhere.
About Lightspeed
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer and Health sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 400 companies globally, including Snap, Nest, Nutanix, AppDynamics, MuleSoft, OYO, Guardant, Affirm, and GrubHub. Lightspeed and its affiliates currently manage $10.5B across the global Lightspeed platform, with investment professionals and advisors in Silicon Valley, Israel, India, China, Southeast Asia, and Europe. www.lsvp.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 14:00:00 CEST | Press release
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duratio
Ouster Releases The REV8 OS Family: The World’s First Native Color Lidar4.5.2026 12:00:00 CEST | Press release
Powered by the Company’s breakthrough L4 and L4 Max Ouster SiliconFeatures the first patented native color lidar sensors with point for point 3D color visionIntroduces flagship OS1 Max sensor with double the range and resolution of Rev7Auto-grade, cybersecure, and designed for functional-safety Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, announced today its new family of OS digital lidar sensors, Rev8, powered by its next-generation L4 Ouster Silicon. Ouster Rev8 features the world’s first patented native color lidar sensors, provides up to double the range and resolution of the previous generation, and is designed for functional safety, reliability, affordability, and scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504718668/en/ The REV8 OS Family: The World's First Native Color Lidar. L4 Ouster Silicon: Ouster’s breakthrough L4 architecture doubles t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom